使伊波拉病毒醣蛋白失去穩定性會導致病毒無法 繼續在細胞內複製。降低醣蛋白的穩定性可以防 止病毒與核內體膜融合。目前我們正在整理相關 研究成果，預期將於一些具有影響力的期刊上發 表。我們會繼續研究，直到研發出針對伊波拉病 毒的藥物。」 牛津之路 問及如何獲得在牛津大學實習的機會，Shaikh 表示，這不是一場競賽。他與Stuarts教授和 Yvonne Jones教授共同參加了面試。「面試持續 了大概30分鐘，問題與我之前的經驗和計算機藥 物設計技能有關。一切都進行得很順利。」 can bind to Ebola and destabilise Ebola in thermos-stability assay. ‘I didn’t have much time at Oxford and the clock was ticking, so I proceeded everything in one shot. We’ve got some compounds that work. And I’m so proud and thrilled that four compounds from my list were purchased by Oxford from the same private company. ! e cost of each compound di" ers. All compounds cost around 1,000 USD in total,’ says Shaikh. What Shaikh achieved at Oxford far exceeded his expectations. In the beginning, Shaikh just wanted to see how the Oxford research group executed their work. ! en he performed his task very well and contributed to a new discovery. ‘We have also got the Crystallography structure of compound bound to Ebola glycoprotein,’ he says. Decreasing the stability of GP the inhibitor could prevent the fusion of the virus with endosomal membranes. We are currently # nalising the results and will publish a paper in some good impact journals for this collaboration between UM and Oxford. We will keep working on Ebola until we get something.’ Way to Oxford As to how to get accepted by Oxford, Shaikh hints that it is not about competition. He attended an interview with Prof Stuarts and Prof Yvonne Jones. ‘It lasted about 30 minutes, with questions related to my previous experience and computational drug design skills, and that is it. Fortunately, things went smoothly,’ Shaikh says. Solid Research Experience at UM Shaikh attributes the internship to his PhD supervisor Siu Weng In, an assistant professor from the Faculty of Science and Technology. ‘It is Prof Siu Shaikh與導師蕭詠然教授 Shaikh and his PhD supervisor Siu Weng In Shaikh參與針對伊波拉病毒的藥物設計 Shaikh works on his Ebola drug design project at Oxford 人物專訪• INTERVIEW 40
RkJQdWJsaXNoZXIy MTQ1NDU2Ng==